

Hope S Rugo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/818381/publications.pdf>

Version: 2024-02-01

382
papers

48,988
citations

2544

96
h-index

1900

208
g-index

391
all docs

391
docs citations

391
times ranked

42869
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. British Journal of Cancer, 2022, 126, 265-274.	6.4	8
2	A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast, 2022, 61, 156-167.	2.2	12
3	Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study. JMIR Cancer, 2022, 8, e31756.	2.4	0
4	Role of Fcγ receptors in HER2-targeted breast cancer therapy. , 2022, 10, e003171.		47
5	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 282-293.	1.6	88
6	Risk-Based Screening for Cancer in Patients With Dermatomyositis. JAMA Dermatology, 2022, 158, 244.	4.1	6
7	OUP accepted manuscript. Oncologist, 2022, , .	3.7	4
8	Emerging treatment strategies for metastatic triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210869.	3.2	15
9	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Npj Breast Cancer, 2022, 8, 23.	5.2	67
10	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
11	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Frontiers in Oncology, 2022, 12, 802579.	2.8	5
12	The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases. Breast, 2022, 63, 149-156.	2.2	2
13	Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 345-348.	3.1	10
14	Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer. Journal of Oncology, 2022, 2022, 1-9.	1.3	0
15	NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 436-442.	4.9	23
16	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	2.5	15
17	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell, 2022, 40, 609-623.e6.	16.8	92
18	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387, 9-20.	27.0	854

#	ARTICLE	IF	CITATIONS
19	Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.. Journal of Clinical Oncology, 2022, 40, 504-504.	1.6	8
20	The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. , 2022, 10, e004312.		5
21	Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study.. Journal of Clinical Oncology, 2022, 40, 1101-1101.	1.6	0
22	Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.. Journal of Clinical Oncology, 2022, 40, 510-510.	1.6	0
23	Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 2022, 40, 535-535.	1.6	0
24	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptorâ€“positive (HR+), human epidermal growth factor receptor 2â€“negative (HER2â€“) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. Journal of Clinical Oncology, 2022, 40, 1006-1006.	1.6	4
25	Sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. Journal of Clinical Oncology, 2022, 40, 1071-1071.	1.6	7
26	Imaging of solid tumors using 68Ga-FAP-2286.. Journal of Clinical Oncology, 2022, 40, 3059-3059.	1.6	0
27	Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 691-722.	4.9	357
28	Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.. Journal of Clinical Oncology, 2022, 40, TPS1121-TPS1121.	1.6	2
29	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS611-TPS611.	1.6	1
30	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nature Communications, 2022, 13, .	12.8	21
31	Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (Pts) with hormone receptorâ€“positive/HER2-negative (HR+/HER2-) advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, LBA1001-LBA1001.	1.6	68
32	Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptorâ€“negative (HR+/HER2â€“) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).. Journal of Clinical Oncology, 2022, 40, 1015-1015.	1.6	2
33	Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO Precision Oncology, 2022, , .	3.0	4
34	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1118-TPS1118.	1.6	2
35	Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptorâ€“positive/human epidermal growth factor receptor 2â€“negative advanced breast cancer (ER+/HER2â€“ ABC): Analyses from PALOMA-2.. Journal of Clinical Oncology, 2022, 40, LBA1003-LBA1003.	1.6	95
36	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	6.3	22

#	ARTICLE	IF	CITATIONS
37	Planning for postpandemic cancer care delivery: Recovery or opportunity for redesign?. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 34-46.	329.8	10
38	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	2.4	140
39	Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. <i>Oncologist</i> , 2021, 26, e53-e65.	3.7	64
40	Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. <i>Lancet Oncology</i> , The, 2021, 22, 27-28.	10.7	9
41	Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data. , 2021, , .		2
42	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 179-190.	2.5	5
43	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	6.3	171
44	Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer. , 2021, , .		0
45	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 155-165.	2.5	18
46	Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2021, 81, GS3-01-GS3-01.	0.9	16
47	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	2.4	7
48	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	10.7	169
49	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	3.7	33
50	An Overview of PARP Inhibitors for the Treatment of Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 255-282.	3.6	182
51	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2~ Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). <i>Clinical Cancer Research</i> , 2021, 27, 4177-4185.	7.0	47
52	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 603.	7.1	37
53	Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 457-467.	1.4	10
54	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. <i>Lancet Oncology</i> , The, 2021, 22, 489-498.	10.7	157

#	ARTICLE	IF	CITATIONS
55	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	27.0	601
56	Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3275-3277.	7.0	0
57	In Reply. <i>Oncologist</i> , 2021, 26, e1286-e1287.	3.7	0
58	Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 387-395.	2.5	8
59	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab025.	2.9	8
60	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	7.1	217
61	Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-PIK3CA-Mutated Breast Cancer. <i>Oncologist</i> , 2021, 26, e1133-e1142.	3.7	17
62	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	3.7	9
63	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	1.6	153
64	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	6.3	83
65	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	7.0	11
66	A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes. <i>Clinical Cancer Research</i> , 2021, 27, 4486-4490.	7.0	7
67	Trials of Immunotherapy in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 171-185.	1.0	1
68	Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 369-377.	2.5	6
69	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. <i>Oncologist</i> , 2021, 26, e1339-e1346.	3.7	16
70	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	2.5	19
71	Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor -Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	1.6	23
72	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	3.7	28

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply. Lancet, The, 2021, 398, 24-25.	13.7	1
74	Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3959-3977.	1.6	121
75	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	1.6	76
76	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Research, 2021, 23, 87.	5.0	21
77	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast, 2021, 58, 18-26.	2.2	3
78	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
79	A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncology, 2021, 17, 3911-3924.	2.4	9
80	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	2.4	26
81	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology, 2021, 7, 1654.	7.1	42
82	Expert Discussion: Predictive Markers. Breast Care, 2021, 16, 1-6.	1.4	0
83	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. Npj Breast Cancer, 2021, 7, 113.	5.2	10
84	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	1.2	354
85	NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 484-493.	4.9	186
86	Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?. Npj Breast Cancer, 2021, 7, 139.	5.2	3
87	THE ALPESIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC). Breast, 2021, 59, S49.	2.2	0
88	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications, 2021, 12, 6428.	12.8	36
89	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer, 2020, 20, e251-e260.	2.4	15
90	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist, 2020, 25, e214-e222.	3.7	39

#	ARTICLE	IF	CITATIONS
91	Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. <i>European Journal of Surgical Oncology</i> , 2020, 46, 223-228.	1.0	5
92	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. <i>Clinical Breast Cancer</i> , 2020, 20, e173-e180.	2.4	21
93	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Breast Journal</i> , 2020, 26, 368-375.	1.0	8
94	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 110-121.	7.0	120
95	Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>JAMA Surgery</i> , 2020, 155, e195410.	4.3	81
96	Corrigendum to “Efficacy+ safety of palbociclib (P) in patients (pts) ≥50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11-12]. <i>Breast</i> , 2020, 49, 131.	2.2	0
97	Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). <i>Journal of Clinical Pharmacology</i> , 2020, 60, 444-452.	2.0	7
98	Talazoparib in Patients with a Germline <i>BRCA</i> -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. <i>Oncologist</i> , 2020, 25, e439-e450.	3.7	61
99	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	10.7	826
100	Identifying tests related to breast cancer care in claims data. <i>Breast Journal</i> , 2020, 26, 1227-1230.	1.0	0
101	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3584.	12.8	115
102	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i> , The, 2020, 396, 1817-1828.	13.7	992
103	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	2.5	21
104	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
105	Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	7.1	119
106	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2+ metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 161-172.	2.5	3
107	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	4.5	29
108	A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial. <i>Global Advances in Health and Medicine</i> , 2020, 9, 216495612096471.	1.6	5

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <sc>KEYNOTE</sc>â€”158 and <sc>KEYNOTE</sc>â€”028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	5.1	288
110	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Annals of Oncology, 2020, 31, 1001-1010.	1.2	99
111	Management of Cancer Cachexia: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 2438-2453.	1.6	292
112	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Research and Treatment, 2020, 181, 623-633.	2.5	6
113	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	3.8	3
114	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research, 2020, 26, 1105-1113.	7.0	19
115	<p></p>Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab</p>. OncoTargets and Therapy, 2020, Volume 13, 4385-4395.	2.0	6
116	Genomewide Metaâ€”Analysis Validates a Role for <i>S1PR1</i> in Microtubule Targeting Agentâ€”Induced Sensory Peripheral Neuropathy. Clinical Pharmacology and Therapeutics, 2020, 108, 625-634.	4.7	25
117	Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment. Breast Journal, 2020, 26, 1472-1474.	1.0	0
118	MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Reports, 2020, 30, 3368-3382.e7.	6.4	44
119	Methylome Variation Predicts Exemestane Resistance in Advanced ER⁺ Breast Cancer. Technology in Cancer Research and Treatment, 2020, 19, 153303381989633.	1.9	5
120	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptorâ€”positive/human epidermal growth factor receptor 2â€”negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research, 2020, 22, 27.	5.0	24
121	Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clinical Cancer Research, 2020, 26, 4743-4747.	7.0	0
122	Clinical Significance of Circulating Tumor Cells in Hormone Receptorâ€”positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clinical Cancer Research, 2020, 26, 4911-4920.	7.0	14
123	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physicianâ€™s Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz085.	2.9	24
124	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. Journal of Clinical Oncology, 2020, 38, 1070-1080.	1.6	19
125	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 676.	7.1	419
126	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer, 2020, 20, 183-193.	2.4	13

#	ARTICLE	IF	CITATIONS
127	Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 23-29.	2.5	3
128	TROPICS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	2.4	62
129	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3059-3082.	2.9	61
130	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. <i>Cancer Research</i> , 2020, 80, CT011-CT011.	0.9	18
131	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1000-1000.	1.6	135
132	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1006-1006.	1.6	52
133	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS596-TPS596.	1.6	12
134	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 370-382.	2.2	18
135	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 12-22.	4.9	70
136	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 452-478.	4.9	848
137	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	6.3	55
138	Achieving Improved Survival Outcomes in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 371-372.	27.0	15
139	Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985423.	3.2	87
140	A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. <i>Npj Breast Cancer</i> , 2019, 5, 17.	5.2	19
141	The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 5-15.	2.5	48
142	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. <i>Oncologist</i> , 2019, 24, 1514-1525.	3.7	49
143	Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 401-408.	2.5	18
144	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1929-1940.	27.0	1,582

#	ARTICLE	IF	CITATIONS
145	ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. <i>Future Oncology</i> , 2019, 15, 2211-2225.	2.4	16
146	Localâ€‘regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	2.5	30
147	Fixed combination of oral NEPA (netupitantâ€‘palonosetron) for the prevention of acute and delayed chemotherapyâ€‘induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, doubleâ€‘blind phase III studies. <i>Cancer Medicine</i> , 2019, 8, 2064-2073.	2.8	14
148	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€‘Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	1.6	229
149	T-Cellâ€‘Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019, 37, 318-327.	1.6	656
150	Breast Cancer, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 118-126.	4.9	158
151	Biosimilars for HER2-Positive Breast Cancer. , 2019, , 231-237.		0
152	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	27.0	542
153	Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz058.	2.9	4
154	A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2â€‘ ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR. <i>Breast</i> , 2019, 48, S48.	2.2	0
155	Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop. <i>American Journal of Hospice and Palliative Medicine</i> , 2019, 36, 143-146.	1.4	6
156	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , 2019, 25, 2433-2441.	7.0	62
157	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	7.0	102
158	Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 719-729.	2.5	265
159	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptorâ€‘Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	7.1	187
160	Demystifying biosimilars: development, regulation and clinical use. <i>Future Oncology</i> , 2019, 15, 777-790.	2.4	17
161	A Pharmacogenetic Prediction Model of Progressionâ€‘Free Survival in Breast Cancer using Genomeâ€‘Wide Genotyping Data from CALGB 40502 (Alliance). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 738-745.	4.7	11
162	Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA</i> -mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1040-1040.	1.6	15

#	ARTICLE	IF	CITATIONS
163	Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 486-489.	0.3	0
164	Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 555-558.	0.3	1
165	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 497-509.	10.7	530
166	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 547-557.	2.5	32
167	The new world of biosimilars in oncology: Translation of data to the clinic. <i>European Journal of Cancer</i> , 2018, 96, 125-127.	2.8	2
168	Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etrinecan Pegol. <i>Clinical Cancer Research</i> , 2018, 24, 3348-3357.	7.0	18
169	Stomatitis associated with mammalian target of rapamycin inhibition. <i>Journal of the American Dental Association</i> , 2018, 149, 291-298.	1.5	15
170	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). <i>Breast Cancer Research and Treatment</i> , 2018, 169, 1-7.	2.5	12
171	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 26-27.	0.4	7
172	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. <i>Annals of Oncology</i> , 2018, 29, 888-894.	1.2	104
173	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 271-280.	1.4	33
174	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. <i>Cancer Cell</i> , 2018, 33, 60-74.e6.	16.8	270
175	Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 1486-1499.	7.0	41
176	Circulating Tumors Cells as a Biomarker of Radiation Benefit. <i>JAMA Oncology</i> , 2018, 4, e180194.	7.1	4
177	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811.	7.0	249
178	Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 117-122.	2.5	20
179	Emerging data on improving response to hormone therapy: the role of novel targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 3-18.	2.4	2
180	Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 19-28.	2.4	57

#	ARTICLE	IF	CITATIONS
181	Phosphatidylinositol 3-Kinase Î±â€™Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	1.6	298
182	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 315-326.	2.2	14
183	Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1037-1042.	1.3	2
184	Efficacy + safety of palbociclib (P) in patients (pts) â‰¥50 y with hormone receptorâ€™positive (HR+)/human epidermal growth factor receptor 2â€™negative (HER2â€™) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. <i>Breast</i> , 2018, 41, S11-S12.	2.2	0
185	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	27.0	3,097
186	Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 31.	5.2	23
187	Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 489-497.	2.4	25
188	Palbociclib plus endocrine therapy in older women with HR+/HER2â€™ advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018, 101, 123-133.	2.8	59
189	The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. <i>Future Oncology</i> , 2018, 14, 2461-2469.	2.4	9
190	Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 829-837.	4.9	6
191	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	27.0	1,472
192	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	7.0	14
193	Reply to the letter to the editor â€™Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analysesâ€™™ by Kaiser et al.. <i>Annals of Oncology</i> , 2018, 29, 1878.	1.2	0
194	The association of early toxicity and outcomes for patients treated with abemaciclib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1053-1053.	1.6	7
195	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1059-1059.	1.6	38
196	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 110-110.	1.6	4
197	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 1873-1886.	1.4	5
198	Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 533-537.	0.3	0

#	ARTICLE	IF	CITATIONS
199	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncology, 2017, 3, 1043.	7.1	98
200	Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 606.	7.4	127
201	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 37.	7.4	129
202	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer, 2017, 25, 1127-1135.	2.2	37
203	Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Research and Treatment, 2017, 165, 151-159.	2.5	47
204	Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS Journal, 2017, 19, 1411-1423.	4.4	7
205	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	7.0	492
206	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 2017, 165, 329-341.	2.5	40
207	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 163, 535-544.	2.5	16
208	Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 654-662.	10.7	154
209	Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast, 2017, 33, 76-82.	2.2	8
210	Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Research and Treatment, 2017, 163, 199-205.	2.5	61
211	Breast Cancer- Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 290-303.	329.8	649
212	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	13.7	948
213	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2017, 3, 31.	5.2	64
214	Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012); Tj ETQq0 0.5gBT /Overlock 10 T	0.5	0
215	Use of Neoadjuvant Platinum- The Ongoing Conundrum. JAMA Oncology, 2017, 3, 1312.	7.1	1
216	Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer- Reply. JAMA Oncology, 2017, 3, 1142.	7.1	0

#	ARTICLE	IF	CITATIONS
217	Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. <i>Cancer Research</i> , 2017, 77, 4530-4541.	0.9	44
218	NCCN Guidelines Insights: Antiemesis, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 883-893.	4.9	137
219	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	2.5	25
220	Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 313.	7.1	115
221	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 403-418.	1.6	4
222	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1520-1541.	4.9	104
223	Dual HER2 Blockade. <i>Breast Care</i> , 2017, 12, 345-349.	1.4	1
224	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1â€Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 4035-4041.	1.6	375
225	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541.	1.6	383
226	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1008-1008.	1.6	99
227	Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 607-614.	0.3	1
228	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e40-e54.	3.8	29
229	When to Treat, With What, and for How Long: That Is the Question!. <i>Journal of Oncology Practice</i> , 2016, 12, 1160-1162.	2.5	0
230	Adaptive Randomization of Veliparibâ€Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	27.0	467
231	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 336-342.	1.3	9
232	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1357-1370.	4.9	82
233	Endocrine Therapy for Hormone Receptorâ€Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3069-3103.	1.6	456
234	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	1.6	101

#	ARTICLE	IF	CITATIONS
235	A clinician's guide to biosimilars in oncology. Cancer Treatment Reviews, 2016, 46, 73-79.	7.7	74
236	Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Medicine, 2016, 5, 1897-1907.	2.8	62
237	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist, 2016, 21, 1165-1175.	3.7	183
238	Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1925-1936.	27.0	1,943
239	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine, 2016, 22, 1321-1329.	30.7	138
240	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Research and Treatment, 2016, 155, 521-530.	2.5	27
241	HER2-positive breast cancer: is more treatment better?. Lancet Oncology, The, 2016, 17, 268-270.	10.7	2
242	Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2016, 16, 18-22.	2.4	22
243	Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Research and Treatment, 2016, 155, 569-578.	2.5	20
244	Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Annals of Oncology, 2016, 27, 519-525.	1.2	68
245	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 29.	7.1	68
246	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology, 2016, 34, 419-426.	1.6	203
247	Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clinical Breast Cancer, 2016, 16, 8-17.	2.4	75
248	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e40-e54.	3.8	16
249	Utility of patient-derived lymphoblastoid cell lines as an <i>ex vivo</i> capecitabine sensitivity prediction model for breast cancer patients. Oncotarget, 2016, 7, 38359-38366.	1.8	4
250	Cancer-Related Fatigue, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1012-1039.	4.9	581
251	Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Research, 2015, 17, 73.	5.0	55
252	The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Management and Research, 2015, 7, 175.	1.9	10

#	ARTICLE	IF	CITATIONS
253	Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Research and Treatment, 2015, 154, 339-349.	2.5	57
254	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1556-1568.	10.7	79
255	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. Journal of Clinical Oncology, 2015, 33, 340-348.	1.6	94
256	Practice Patterns in the Delivery of Radiation Therapy After Mastectomy Among the University of California Athena Breast Health Network. Clinical Breast Cancer, 2015, 15, 43-47.	2.4	15
257	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	27.0	598
258	Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clinical Therapeutics, 2015, 37, 134-144.	2.5	13
259	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research, 2015, 21, 2911-2915.	7.0	77
260	Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Research and Treatment, 2015, 153, 173-181.	2.5	17
261	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	3.0	128
262	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer, 2015, 121, 1937-1948.	4.1	8
263	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33, 2361-2369.	1.6	197
264	SIS.NET: A randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer, 2015, 121, 893-899.	4.1	46
265	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Research and Treatment, 2015, 149, 439-448.	2.5	50
266	Chemotherapy-related amenorrhea after adjuvant paclitaxel+trastuzumab (APT trial). Breast Cancer Research and Treatment, 2015, 151, 589-596.	2.5	65
267	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment, 2015, 150, 605-611.	2.5	19
268	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1902-1909.	1.6	351
269	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 2722-2729.	7.0	57
270	Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Therapeutic Advances in Medical Oncology, 2015, 7, 321-339.	3.2	36

#	ARTICLE	IF	CITATIONS
271	PO139 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B (RANK) EXPRESSION IN PRIMARY BREAST CANCER CORRELATES WITH RECURRENCE FREE SURVIVAL AND DEVELOPMENT OF BONE METASTASES IN THE I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast</i> , 2015, 24, S69-S70.	2.2	0
272	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1098-1105.	7.0	35
273	Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1511-1513.	7.0	6
274	Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer. <i>Cancer Research</i> , 2015, 75, PD5-1-PD5-1.	0.9	7
275	A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. <i>PLoS ONE</i> , 2015, 10, e0141166.	2.5	22
276	A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 99-106.	2.5	16
277	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. <i>Cancer Cell</i> , 2014, 26, 623-637.	16.8	751
278	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. <i>Cancer</i> , 2014, 120, 2657-2664.	4.1	47
279	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3840-3847.	1.6	253
280	Hormone Therapy in Premenopausal Women with Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 175-176.	27.0	13
281	Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 459-467.	2.5	74
282	Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. <i>International Journal of Hyperthermia</i> , 2014, 30, 285-294.	2.5	93
283	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor -Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1472-1479.	1.6	31
284	Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 725-734.	2.5	67
285	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2142-2150.	1.6	207
286	The cancer glycocalyx mechanically primes integrin-mediated growth and survival. <i>Nature</i> , 2014, 511, 319-325.	27.8	610
287	Senior Adult Oncology, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 82-126.	4.9	116
288	Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 151-151.	1.6	1

#	ARTICLE	IF	CITATIONS
289	Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 3-21; quiz 22.	0.3	22
290	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	2.4	104
291	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 654-663.	6.3	88
292	Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5505-5512.	7.0	592
293	Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 461-470.	2.5	38
294	A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 411-419.	2.5	23
295	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. <i>Advances in Therapy</i> , 2013, 30, 870-884.	2.9	430
296	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013, 119, 1908-1915.	4.1	81
297	Genomic Profiling of Isolated Circulating Tumor Cells from Metastatic Breast Cancer Patients. <i>Cancer Research</i> , 2013, 73, 30-40.	0.9	92
298	Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 1-12.	2.5	25
299	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3693-3702.	7.0	270
300	First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER. <i>Oncologist</i> , 2013, 18, 501-510.	3.7	63
301	Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab. <i>Clinical Cancer Research</i> , 2013, 19, 2745-2754.	7.0	62
302	Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2013, 19, 2817-2823.	7.0	21
303	Health-related quality of life and disease symptoms in postmenopausal women with HR ⁺ , HER2 ⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	1.9	24
304	Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. <i>Journal of the National Cancer Institute</i> , 2013, 105, 104-112.	6.3	100
305	Myeloid Growth Factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1266-1290.	4.9	53
306	Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA509-LBA509.	1.6	49

#	ARTICLE	IF	CITATIONS
307	Temporary amenorrhea predicts future infertility in young women treated with chemotherapy. <i>Journal of Cancer Therapeutics & Research</i> , 2013, 2, 16.	1.2	5
308	Leukocyte composition of human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2796-2801.	7.1	393
309	The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression. <i>Cancer Discovery</i> , 2012, 2, 638-651.	9.4	61
310	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. <i>Journal of Clinical Oncology</i> , 2012, 30, 3444-3447.	1.6	18
311	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. <i>Journal of Clinical Oncology</i> , 2012, 30, 3234-3241.	1.6	319
312	Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. <i>Future Oncology</i> , 2012, 8, 1383-1396.	2.4	12
313	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2615-2623.	1.6	413
314	Senior Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 162-209.	4.9	105
315	Antiemesis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 456-485.	4.9	44
316	The role of targeted therapy and biomarkers in breast cancer treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 807-819.	3.3	36
317	The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1327-1335.	2.5	19
318	Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIALâ€CALGB 150007/150012, ACRIN 6657. <i>Journal of Clinical Oncology</i> , 2012, 30, 3242-3249.	1.6	379
319	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 875-883.	2.5	51
320	Associations Between Pro- and Anti-Inflammatory Cytokine Genes and Breast Pain in Women Prior to Breast Cancer Surgery. <i>Journal of Pain</i> , 2012, 13, 425-437.	1.4	78
321	Everolimus in Postmenopausal Hormone-Receptorâ€Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	27.0	2,474
322	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 591-601.	2.3	72
323	Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. <i>Journal of Cancer Survivorship</i> , 2012, 6, 324-332.	2.9	95
324	An openâ€label, phase 2 trial of RPL4610 (angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012, 118, 4098-4104.	4.1	33

#	ARTICLE	IF	CITATIONS
325	Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Research and Treatment, 2012, 132, 1107-1118.	2.5	109
326	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 2012, 132, 1049-1062.	2.5	286
327	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 134, 13-20.	2.5	48
328	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Research and Treatment, 2012, 133, 1067-1075.	2.5	103
329	Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) â€“Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology, 2011, 29, 398-405.	1.6	647
330	Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 372-381.	7.0	89
331	Immune microenvironments in solid tumors: new targets for therapy. Genes and Development, 2011, 25, 2559-2572.	5.9	277
332	A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 6897-6904.	7.0	90
333	Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2459-2465.	1.6	95
334	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	7.0	28
335	Reducing the Long-term Effects of Chemotherapy in Young Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 312-4.	7.4	20
336	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	9.4	1,486
337	Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research, 2011, 17, 4834-4843.	7.0	318
338	RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4286-4293.	1.6	379
339	Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 33-38.	2.0	54
340	Cost Comparison of Capecitabine in Patients With Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 550-556.	1.3	6
341	Cancer-Related Fatigue. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 904-931.	4.9	201
342	Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1331-1339.	4.9	58

#	ARTICLE	IF	CITATIONS
343	Amelioration of sexual adverse effects in the early breast cancer patient. <i>Journal of Cancer Survivorship</i> , 2010, 4, 247-255.	2.9	30
344	The cardiac safety of trastuzumab in the treatment of breast cancer. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 335-346.	2.4	58
345	Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 77-82.	1.6	131
346	Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials. <i>Clinical Breast Cancer</i> , 2010, 10, 288-293.	2.4	19
347	Antiemesis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 572-595.	4.9	43
348	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2630-2637.	1.6	582
349	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. <i>Journal of Clinical Oncology</i> , 2009, 27, 6117-6123.	1.6	26
350	Image-Detected Breast Cancer: State-of-the-Art Diagnosis and Treatment. <i>Journal of the American College of Surgeons</i> , 2009, 209, 504-520.	0.5	147
351	Implementing decision and communication aids to facilitate patient-centered care in breast cancer: A case study. <i>Patient Education and Counseling</i> , 2009, 77, 360-368.	2.2	52
352	A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1139-1148.	2.3	52
353	New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 25-33.	4.3	38
354	Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. <i>Journal of Neuro-Oncology</i> , 2008, 88, 359-365.	2.9	67
355	Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable. <i>Clinical Breast Cancer</i> , 2008, 8, 33-37.	2.4	14
356	Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. <i>Lancet Oncology</i> , The, 2008, 9, 602-603.	10.7	9
357	Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2008, 26, 1810-1816.	1.6	475
358	A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7878-7883.	7.0	109
359	Quantitative and Clinical Description of Postural Instability in Women With Breast Cancer Treated With Taxane Chemotherapy. <i>Archives of Physical Medicine and Rehabilitation</i> , 2007, 88, 1002-1008.	0.9	123
360	Hormonal Therapy for Advanced Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 273-291.	2.2	3

#	ARTICLE	IF	CITATIONS
361	Bevacizumab for Advanced Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 303-319.	2.2	22
362	Strategies for the Prevention of Treatment-Related Bone Loss in Women Receiving Adjuvant Hormonal Therapy. Clinical Breast Cancer, 2007, 7, S21-S28.	2.4	9
363	Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Research and Treatment, 2007, 105, 17-28.	2.5	89
364	The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations. Current Treatment Options in Oncology, 2007, 8, 47-60.	3.0	29
365	Cytoreduction of Lymphoid Malignancies and Mobilization of Blood Hematopoietic Progenitor Cells with High Doses of Cyclophosphamide and Etoposide Plus Filgrastim. Biology of Blood and Marrow Transplantation, 2006, 12, 316-324.	2.0	13
366	Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer and Metastasis Reviews, 2006, 25, 279-292.	5.9	25
367	High-Dose Etoposide, Thiopeta, and Dose-Adjusted Carboplatin (TVCa) With Autologous Hematopoietic Stem Cell Rescue as Treatment of Relapsed or Refractory Germ Cell Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 130-137.	1.3	7
368	Patient and Physician Attitudes Toward Breast Cancer Clinical Trials: Developing Interventions Based on Understanding Barriers. Clinical Breast Cancer, 2005, 6, 45-54.	2.4	54
369	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study. Journal of Clinical Oncology, 2005, 23, 5464-5473.	1.6	271
370	Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal of Clinical Oncology, 2005, 23, 5474-5483.	1.6	470
371	Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs: the Investigational Drugs Journal, 2005, 8, 739-54.	0.7	3
372	Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: Effect of clinical node status at presentation. Journal of the American College of Surgeons, 2004, 199, 856-862.	0.5	50
373	Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy and Pharmacology, 2004, 53, 468-474.	2.3	7
374	Management of breast cancer diagnosed during pregnancy. Current Treatment Options in Oncology, 2003, 4, 165-173.	3.0	69
375	The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Seminars in Oncology, 2003, 30, 749-762.	2.2	69
376	Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial. Journal of Clinical Oncology, 2001, 19, 3771-3779.	1.6	185
377	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. Annals of Surgical Oncology, 2001, 8, 549-559.	1.5	185
378	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. Annals of Surgical Oncology, 2001, 8, 549-559.	1.5	2

#	ARTICLE	IF	CITATIONS
379	Autologous stem cell transplantation for acute myeloid leukemia in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 50-57.	2.0	52
380	Bone Marrow Transplantation Retinopathy in the Absence of Radiation Therapy. <i>American Journal of Ophthalmology</i> , 1996, 122, 268-270.	3.3	13
381	Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. <i>International Immunology</i> , 1990, 2, 821-832.	4.0	357
382	Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. <i>American Journal of Medicine</i> , 1989, 87, 605-613.	1.5	44